Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

BioRay Pharmaceutical Files HKEX IPO, Backed by First‑in‑Class Autoimmune and Oncology Pipeline

Fineline Cube Jan 22, 2026
Company Deals

BMS Partners with Microsoft on AI‑Powered NSCLC Detection Platform

Fineline Cube Jan 22, 2026
Company Deals

Bayer Partners with Vanderbilt in 5‑Year Deal to Accelerate Cardio‑Renal Drug Discovery

Fineline Cube Jan 22, 2026
Company Deals

Hangzhou Diagens Biotechnology Files HKEX IPO for Medical Imaging AI Platform

Fineline Cube Jan 22, 2026
Company Deals

GSK Acquires RAPT Therapeutics for $2.2 Billion, Adding Ozureprubart for Food Allergy Protection

Fineline Cube Jan 22, 2026
Company Drug Policy / Regulatory

Merson’s Bemejing Wins First CNMR “Overseas Version” Drug Price Certificate

Fineline Cube Jan 21, 2026
Company Deals Drug

Alteogen Licenses ALT‑B4 Hyaluronidase to Tesaro for $285M Subcutaneous Dostarlimab Deal

Fineline Cube Jan 22, 2026
Company Drug

Shanghai Pharma’s iNKT Cell Therapy B023 Gets NMPA Nod for Advanced Solid Tumors

Fineline Cube Jan 22, 2026
Company Drug Policy / Regulatory

National Drug Alliance Moves VBP 11th‑Round Information Disclosure Conference to 27 Oct 2025 in Shanghai

Fineline Cube Oct 11, 2025

The National Drug Alliance Procurement Office announced a schedule change for the 11th round of...

Company Deals

Novo Nordisk to Acquire Akero Therapeutics for $5.2 Billion, Secures Future Value with Efruxifermin

Fineline Cube Oct 10, 2025

Novo Nordisk A/S (NYSE: NVO) announced today that it will acquire Akero Therapeutics (NASDAQ: AKRO) for...

Company Drug

Xingqi Pharma Secures NMPA Approval for SQ‑129, a Novel Treatment for Diabetic Macular Edema

Fineline Cube Oct 10, 2025

China‑based Shenyang Xingqi Pharmaceutical Co., Ltd. (SHE: 300573) announced today that the China National Medical...

Company Drug

Shanghai Henlius Biotech Achieves Primary Endpoint in Phase 3 Trial of Serplulimab for Early‑Stage Gastric Cancer

Fineline Cube Oct 10, 2025

Shanghai Henlius Biotech Inc. (HKG: 2696) today announced that its phase 3, randomized, double‑blind, multi‑center study...

Company Drug

JW (Cayman) Therapeutics Secures NMPA Acceptance for Carteyva, Introducing In‑House Lentiviral Vector Production

Fineline Cube Oct 10, 2025

JW (Cayman) Therapeutics Co. Ltd (HKG: 2126) announced today that the National Medical Products Administration...

Company Medical Device

Acotec Scientific Receives FDA 510(k) Clearance for Endovenous Radiofrequency Ablation System

Fineline Cube Oct 10, 2025

Acotec Scientific Holdings Limited (HKG: 6669) announced on October 7, 2025 that its Endovenous Radiofrequency Ablation System...

Company Drug

Beijing Luzhu Biotechnology Completes U.S. Phase 1 Trial of LZ901, Demonstrating Strong Safety and Immunogenicity

Fineline Cube Oct 10, 2025

Beijing Luzhu Biotechnology Co., Ltd. (HKG: 2480) announced today that its Phase 1 clinical trial of...

Company Drug

Huadong Medicine Secures NMPA Trial Approval for HDM2017, a CDH17‑Targeting ADC

Fineline Cube Oct 10, 2025

China‑based Huadong Medicine Co., Ltd. (SHE: 000963) announced that its novel antibody‑drug conjugate (ADC), HDM2017...

Company Deals

Chance Pharma Secures Exclusive China Deal with Huadong Medicine for CXG87 Inhaler

Fineline Cube Oct 10, 2025

Hangzhou‑based Chance Pharmaceuticals Co., Ltd. has inked an exclusive commercialization agreement with Shanghai‑listed Huadong Medicine...

Company

Takeda Shuts Down Cell‑Therapy Program, Eyes External Collaboration for γδ T‑Cell Platform

Fineline Cube Oct 10, 2025

Takeda Pharmaceutical Co., Ltd. (TYO: 4502, NYSE: TAK) announced today that it is discontinuing all...

Company Medical Device

Mirxes Secures China’s First Blood‑Test Approval for Gastric‑Cancer Screening

Fineline Cube Oct 9, 2025

Mirxes Holding Company Limited (HKG: 2629) announced that its flagship in‑vitro diagnostic (IVD) test, GASTROClear,...

Company Medical Device

Jenscare Secures LuX‑Valve Approval for Transjugular Tricuspid Replacement in Greater Bay Area

Fineline Cube Oct 9, 2025

Jenscare Scientific Co., Ltd (HKG: 9877) announced that its LuX‑Valve Plus transjugular tricuspid valve replacement...

Company Drug

Roche Secures FDA Approval for Tecentriq‑Lurbinectedin Combo in ES‑SCLC

Fineline Cube Oct 9, 2025

Roche (SWX: ROG, OTCMKTS: RHHBY) announced today that the U.S. Food and Drug Administration (FDA)...

Company Drug

Eli Lilly to Invest $1B in India, Launch New Hyderabad Manufacturing Hub

Fineline Cube Oct 9, 2025

Eli Lilly & Co. (NYSE: LLY) has announced a commitment to invest more than USD 1 billion...

Company Drug

Walvax Biotech Wins Jordan FDA Approval for 13‑Valent Pneumococcal Vaccine

Fineline Cube Oct 9, 2025

China‑based Walvax Biotechnology Co., Ltd. (SHE: 300142) has secured market approval from the Jordan Food...

Company Drug

Northeast Pharma Secures NMPA Approval for DCTY0801 Injection Targeting EGFRvIII‑Positive Brain Gliomas

Fineline Cube Oct 9, 2025

China‑based Northeast Pharmaceutical Group Co., Ltd. (SHE: 000597) has announced that its chimeric antigen receptor...

Company Deals Drug

InnoCare, Zenas, Orelabrutinib: $2 B Licensing Deal Fuels MS Therapeutic Pipeline

Fineline Cube Oct 9, 2025

InnoCare Pharma Limited (HKG: 9969) announced a landmark exclusive license and subscription agreement with Zenas...

Company Drug

Hengrui, SHR‑4298, RAS: China Approves Two Novel Anti‑Tumor Drugs for Clinical Trials

Fineline Cube Oct 9, 2025

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276, HKG: 1276) announced that the National Medical Products Administration...

Company Drug

Shanghai Fosun Secures NMPA Approval for HLX43 + HLX07 Combination in Advanced Solid Tumors

Fineline Cube Oct 9, 2025

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (SHA: 600196) announced that the National Medical Products Administration...

Company Drug

RemeGen & Santen Announce CDE Acceptance of RC28‑E for Diabetic Macular Edema

Fineline Cube Sep 30, 2025

China‑based RemeGen Co., Ltd. (SHA: 688331, HKG: 9995) and Japan’s Santen Pharmaceutical Co., Ltd. confirmed...

Posts pagination

1 … 42 43 44 … 612

Recent updates

  • BioRay Pharmaceutical Files HKEX IPO, Backed by First‑in‑Class Autoimmune and Oncology Pipeline
  • BMS Partners with Microsoft on AI‑Powered NSCLC Detection Platform
  • Bayer Partners with Vanderbilt in 5‑Year Deal to Accelerate Cardio‑Renal Drug Discovery
  • Hangzhou Diagens Biotechnology Files HKEX IPO for Medical Imaging AI Platform
  • Hengrui’s SHR-9839 + HRS-4642 Combo Cleared for Advanced CRC Trials
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

BioRay Pharmaceutical Files HKEX IPO, Backed by First‑in‑Class Autoimmune and Oncology Pipeline

Company Deals

BMS Partners with Microsoft on AI‑Powered NSCLC Detection Platform

Company Deals

Bayer Partners with Vanderbilt in 5‑Year Deal to Accelerate Cardio‑Renal Drug Discovery

Company Deals

Hangzhou Diagens Biotechnology Files HKEX IPO for Medical Imaging AI Platform

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.